7results about How to "Increase activity level" patented technology

The invention discloses a gastrodia elata polypeptide extraction process, and belongs to the technical field of polypeptide extraction. According to the method, gastrodia elata cell membranes are broken through acetone pretreatment, so that protein and lipid are dissociated, trimethylsilyl ether passivates active groups, immobilized enzyme decomposes cellulose and adipose tissues through normal-temperature enzymolysis, a protein stabilizer prevents oxidation and inhibits enzyme activity, differential pressure extraction is combined with a sodium pyrophosphate buffer solution, polypeptide is promoted to be dissolved out, and activity is maintained; the high extraction rate of the gastrodia elata polypeptide and low-active group destructiveness are realized. Reaction sites and binding force are increased by epoxy groups on the surface of an immobilized enzyme carrier prepared by modifying corn starch, enzyme molecules are stable and appropriate due to good biocompatibility, enzyme molecule conformation is optimized through covalent binding, a rigid structure is enhanced, enzyme activity is kept at a high level for a long time, continuous and efficient enzymolysis is performed in gastrodia elata polypeptide extraction, and the gastrodia elata polypeptide extraction efficiency is improved. Compared with the traditional free enzyme, the gastrodia elata polypeptide enzyme has the advantages that the enzyme use cost is reduced, the enzyme consumption and waste generation are reduced, and an efficient and economical scheme is provided for gastrodia elata polypeptide extraction.

The invention relates to the technical field of psychiatric pharmacology, discloses application of helicid in antidepressant drugs, and aims to solve the problems of large side effect, unstable curative effect, drug resistance and the like of existing antidepressant drugs. According to the medicine, through multiple mechanisms of activating a cAMP / PKA / CREB signal channel, promoting neuroplasticity, inhibiting neuronal apoptosis, relieving neuroinflammation and the like, the depressive symptom is remarkably improved. The preparation method comprises the steps of extraction and purification of helicid and preparation of the medicinal preparation. Animal experiments verify that the hilicidum-based antidepressant drug can effectively improve behavioral indexes of depression model rats, has low side effects, and does not have the problem of drug resistance. Compared with the traditional medicine, the medicine provided by the invention has the advantages that the treatment effect is improved, the adverse reaction is reduced, the application prospect is better, and a new medicine choice with a multi-target action mechanism is provided for the treatment of depression.

The invention discloses a preparation method, system and application of cordyceps sobolifera active ingredient powder for glomerular injury repair. The preparation method comprises the following steps: S1, performing low-temperature freeze drying treatment on cordyceps sobolifera; s2, the crushed cordyceps sobolifera is sieved by a 120-mesh sieve, and cordyceps sobolifera powder is obtained; s3, mixing the cordyceps sobolifera powder with a buffer solution containing enzyme according to a solid-liquid ratio of 1g: 10ml, carrying out enzymatic hydrolysis for 2-4 hours under the hydrolysis conditions that the pH value is 4.5-5.5 and the temperature is 37-50 DEG C, and continuously stirring at the speed of 100-300rpm during the enzymatic hydrolysis; s4, after hydrolysis is completed, heating to 80-90 DEG C for 5 minutes; s5, filtering the extracting solution; s6, concentrating the extracting solution by using vacuum evaporation; and S7, packaging the extracting solution in a sealed container by using a sterile technology, and storing under a refrigeration condition of 4-8 DEG C. The cordyceps sobolifera active ingredient powder disclosed by the invention has the capability of repairing damaged glomerulus, and is suitable for preparing medicines for various types of chronic kidney diseases, especially those related to glomerular injury.

The invention provides a novel nano antibody-based recombinant long-acting human growth hormone fusion protein, nucleic acid, a pharmaceutical composition, application and the like. Existing long-acting means of PEGylation, Fc fusion and the like often cause reduction of activity, the human growth hormone is innovatively fused with an anti-albumin nano antibody with a specific sequence, and protein with larger molecules is formed through combination of the nano antibody and albumin antigen, so that the half-life period of the human growth hormone is prolonged, the activity of the human growth hormone is prolonged, and the human growth hormone can be used for preparing the anti-albumin nano antibody. In addition, the activity of the fusion protein provided by the invention is higher than that of a human growth hormone standard substance. The fusion protein and the like have wide industrial application prospects in the field of biological medicines.

The invention belongs to the field of photocatalytic materials, and particularly discloses a CdS-ZnSe heterojunction photocatalytic material with a {002} active crystal face high exposure ratio as well as a preparation method and application of the CdS-ZnSe heterojunction photocatalytic material. The CdS-ZnSe heterojunction is synthesized through a step-by-step reaction strategy. The method comprises the following steps: firstly, synthesizing a CdS nanosheet seed crystal with a hexagonal crystal phase through a cation exchange method, and then controllably preparing the CdS-ZnSe heterojunction with oriented growth in combination with a seed crystal growth method. The rate of the prepared CdS-ZnSe heterojunction for preparing H2 through photocatalytic decomposition of water under the condition of no metal promoter reaches 17.1 mmol.g <-1 >. H <-1 >, and compared with single-component CdS nanosheet seed crystal and ZnSe nanoparticles, the hydrogen production rate of CdS-ZnSe is greatly improved.

The invention discloses a method for increasing the content of gamma-aminobutyric acid in traditional Chinese medicine through fermentation. The method comprises the following steps: S1, superfine grinding of raw materials; s2, performing enzymolysis treatment; s3, fermentation treatment; lactobacillus plantarum and lactobacillus reuteri are selected to be matched for fermentation. A compound enzyme system (cellulase, pectinase and hemicellulase) is added, and the enzyme addition amount is 600 U / g-1400 U / g; the content of GABA in a bacterium synergistic fermentation system is obviously higher than that of a single bacterium fermentation system. Experimental data show that the GABA content can reach 131.5 + / -0.7 [mu] mol / g under the synergistic fermentation condition for 48 h, the GABA content under the lactobacillus plantarum single bacterium fermentation condition and the GABA content under the lactobacillus reuteri single bacterium fermentation condition are 45.5 + / -1.1 [mu] mol / g and 29.9 + / -2.1 [mu] mol / g respectively, the GABA yield is increased by about 2.9-4.4 times through synergistic fermentation, and it is proved that the method can effectively promote efficient conversion and accumulation of glutamic acid into GABA.

A method of compiling a treatment reference table that indicates the responsiveness of one or more specific mutations of α-Gal A to a specific pharmacological chaperone, the method comprising: analysing in vitro the response to the specific pharmacological chaperone in a host cell that has been transformed with a nucleic acid vector that encodes a first mutant α-Gal A and compiling a table listing responsive and non-responsive mutant forms of α-Gal A. The specific pharmacological chaperone is 1-deoxygalactonojirimycin or a pharmaceutically salt or ester and the first cell is HEK-293 MSR cell.